GeneDx (NASDAQ: WGS) has recently received a number of price target changes and ratings updates:
- 10/30/2024 – GeneDx had its price target raised by analysts at The Goldman Sachs Group, Inc. from $54.00 to $70.00. They now have a “neutral” rating on the stock.
- 10/30/2024 – GeneDx had its price target raised by analysts at Wells Fargo & Company from $34.00 to $75.00. They now have an “equal weight” rating on the stock.
- 10/30/2024 – GeneDx had its price target raised by analysts at Craig Hallum from $70.00 to $95.00. They now have a “buy” rating on the stock.
- 10/24/2024 – GeneDx had its price target raised by analysts at Craig Hallum from $46.00 to $70.00. They now have a “buy” rating on the stock.
- 10/16/2024 – GeneDx had its price target raised by analysts at The Goldman Sachs Group, Inc. from $32.00 to $54.00. They now have a “neutral” rating on the stock.
GeneDx Price Performance
Shares of WGS traded up $3.85 on Tuesday, reaching $77.24. The stock had a trading volume of 416,929 shares, compared to its average volume of 446,409. The firm has a 50-day moving average of $52.51 and a 200 day moving average of $36.30. The firm has a market capitalization of $2.12 billion, a PE ratio of -24.84 and a beta of 2.11. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a twelve month low of $1.16 and a twelve month high of $89.11.
GeneDx (NASDAQ:WGS – Get Free Report) last issued its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.25. The business had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business’s quarterly revenue was up 44.3% on a year-over-year basis. During the same period last year, the company posted ($0.82) EPS. Sell-side analysts expect that GeneDx Holdings Corp. will post -0.24 EPS for the current year.
Insiders Place Their Bets
Institutional Investors Weigh In On GeneDx
Several large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. boosted its holdings in shares of GeneDx by 304.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock worth $6,240,000 after buying an additional 110,666 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of GeneDx in the 3rd quarter valued at approximately $2,547,000. Royce & Associates LP acquired a new position in shares of GeneDx in the 3rd quarter valued at approximately $1,201,000. GSA Capital Partners LLP acquired a new position in shares of GeneDx in the 3rd quarter valued at approximately $322,000. Finally, Lisanti Capital Growth LLC acquired a new position in GeneDx during the 3rd quarter worth approximately $1,554,000. Institutional investors own 61.72% of the company’s stock.
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Featured Articles
- Five stocks we like better than GeneDx
- Where to Find Earnings Call Transcripts
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Insider Trades May Not Tell You What You Think
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Retail Stocks Investing, Explained
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for GeneDx Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx Holdings Corp and related companies with MarketBeat.com's FREE daily email newsletter.